We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Breath-Based Biomarkers Identified for Tuberculosis Diagnosis

By LabMedica International staff writers
Posted on 19 Dec 2022
Print article
Image: The R-Tube is designed for ease of use and this non-invasive handheld device is fully self-contained and disposable (Photo courtesy of Respiratory Research)
Image: The R-Tube is designed for ease of use and this non-invasive handheld device is fully self-contained and disposable (Photo courtesy of Respiratory Research)

Tuberculosis (TB) remains one of the top ten causes of death worldwide and is the leading cause of death from a single infectious agent. About a quarter of the world’s population is infected with Mycobacterium tuberculosis (Mtb), and thus at risk of developing TB.

Most conventional diagnostic tests rely on sputum samples, which can be difficult to obtain and have low diagnostic sensitivity in children, HIV-infected individuals and patients with extrapulmonary TB. Therefore, the ideal diagnostic would not rely on sputum samples, and can also detect non-pulmonary TB.

Medical Scientists at the University of Toulouse III-Paul Sabatier (Toulouse, France) and their numerous colleagues included in a study eight patients between 27 and 62 years old, diagnosed with pulmonary TB by direct Ziehl-Neelsen staining and culture of sputum; 21 patients with at least three sputum samples negative for Ziehl-Neelsen staining; children (aged 6–12) were separated into two groups based on the detection or not of mycobacteria; 15 adults (aged 18–61) who presented with community-acquired pneumonia and 15 healthy adult individuals. With the goal of developing a non-sputum-based TB diagnostic, the team examined whether pulmonary TB could be detected in exhaled breath condensate (EBC) samples.

The EBCs were collected using R-tubes (Respiratory Research, Inc, Austin, TX, USA). EBCs were lyophilized and adjusted to a volume of 250 µL of LPS-free water. EBCs were spotted using the Bio-Dot SF blotting apparatus (Bio-Rad, Hercules, CA, USA) and used for Dot-blot immunoassays. The scientists then performed monosaccharide analysis and quantification by capillary electrophoresis monitored by laser-induced fluorescence (CE-LIF). MALDI-TOF analyses were performed on an AB Sciex TOF/TOF 5800 mass spectrometer using the reflectron mode (Framingham, MA, USA).

The investigators reported that that the presence of M. tuberculosis-specific lipids, lipoarabinomannan lipoglycan, and proteins in EBCs can efficiently differentiate baseline TB patients from controls. They used EBCs to track the longitudinal effects of antibiotic treatment in pediatric TB patients. In addition, M. tuberculosis lipoarabinomannan and lipids were structurally distinct in EBCs compared to ex vivo cultured bacteria, revealing specific metabolic and biochemical states of M. tuberculosis in the human lung.

The authors concluded that sampling exhaled air is non-invasive and appears to be a powerful approach that overcomes the limitations in existing assays. An EBC-based approach therefore has potentially broad application for following other pulmonary infectious agents. The study was published on December 14, 2022 in the journal Nature Communications.

Related Links:
University of Toulouse III-Paul Sabatier
Respiratory Research
Bio-Rad
AB Sciex

Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Toxoplasma Gondii Immunoassay
Toxo IgM AccuBind ELISA Kit
New
Dermatophytosis Rapid Diagnostic Kit
StrongStep Dermatophytosis Diagnostic Kit

Print article

Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.